| Business Summary | | Nabi
is
focused
on
the
discovery,
development
and
commercialization
of
products
that
prevent
and
treat
infections
and
autoimmune
diseases.
The
Company
currently
has
an
extensive
pipeline
of
drugs
and
vaccines
in
clinical
and
pre-clinical
development
and
has
four
marketed
biopharmaceutical
products:
Nabi-HB
[Hepatitis
B
Immune
Globulin
(Human)],
WinRho
SDF
[Rho
(D)
Immune
Globulin
Intravenous
(Human)],
Autoplex
T
[Anti-Inhibitor
Coagulant
Complex,
Heat
Treated]
and
Aloprim
[(Allopurinol
sodium)
for
injection].
The
Company
is
also
a
collector
and
supplier
of
specialty
and
non-specific
antibody
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Nabi,
a
biopharmaceutical
company,
has
a
broad
product
portfolio
and
significant
R&D
capabilities
focused
on
the
development
and
commercialization
of
drugs
that
prevent
and
treat
infectious
and
autoimmune
diseases.
For
the
six
months
ended
6/30/01,
sales
rose
11%
to
$125.5
million.
Net
income
before
extraordinary
item
rose
35%
to
$2.2
million.
Revenues
reflect
higher
pricing
and
increased
volumes
of
antibody
products.
Net
income
also
reflects
a
higher
gross
profit. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Gury, 62 Chairman,
Pres and CEO | $561K | -- | Mark Smith, 39 CFO,
Sr. VP-Fin. | -- | -- | Thomas McLain, 43 Exec.
VP, COO | 239K | -- | Bruce Farley, 50 Sr.
VP, Manufacturing Operations | 268K | -- | David Muth, 47 Sr.
VP, Bus. Operations | 271K | $54K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|